Drug class review: Second-generation antidepressants final update 5 report

PURPOSE: We compared the effectiveness and harms of second-generation antidepressants in the treatment of major depressive disorder (MDD), dysthymia, subsyndromal depression, seasonal affective disorder, generalized anxiety disorder, obsessive compulsive disorder, panic disorder, post-traumatic stre...

Full description

Main Author: Gartlehner, Gerald
Corporate Authors: Research Triangle Institute-University of North Carolina Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, Oregon Health & Science University Evidence-based Practice Center, Oregon Health & Science University, Drug Effectiveness Review Project
Format: eBook
Language:English
Published: Portland, Oregon Oregon Health & Science University c2011, 2011
Series:Drug class reviews
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:PURPOSE: We compared the effectiveness and harms of second-generation antidepressants in the treatment of major depressive disorder (MDD), dysthymia, subsyndromal depression, seasonal affective disorder, generalized anxiety disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. DATA SOURCES: We searched PubMed, Embase, PsycINFO, the Cochrane Library, and the International Pharmaceutical Abstracts until September 2010. For additional data we also hand searched reference lists, US Food and Drug Administration medical and statistical reviews and dossiers submitted by pharmaceutical companies. REVIEW METHODS: Study selection, data abstraction, validity assessment, grading the strength of the evidence, and data synthesis were all carried out according to standard Drug Effectiveness Review Project review methods. RESULTS AND CONCLUSIONS: Overall, we found no substantial differences in comparative efficacy and effectiveness of second-generation antidepressants for the treatment of depressive or anxiety disorders. Differences exist in the incidence of specific adverse events and the onset of action. Except for MDD, the evidence is limited to few direct comparisons for most indications. No head-to-head evidence is available for MDD in pediatric populations, dysthymia, subsyndromal depression, seasonal affective disorder, and premenstrual dysphoric disorder
Item Description:"March 2011.". - Title from PDF t.p. (viewed on Sept. 9, 2011)
Physical Description:1 online resource (1 PDF file (190 p.) ill.)